339 related articles for article (PubMed ID: 20713816)
1. Advanced biological therapies for diabetic foot ulcers.
Kirsner RS; Warriner R; Michela M; Stasik L; Freeman K
Arch Dermatol; 2010 Aug; 146(8):857-62. PubMed ID: 20713816
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost.
Zelen CM; Serena TE; Gould L; Le L; Carter MJ; Keller J; Li WW
Int Wound J; 2016 Apr; 13(2):272-82. PubMed ID: 26695998
[TBL] [Abstract][Full Text] [Related]
3. A review of the literature on topical therapies for diabetic foot ulcers. Part 2: Advanced treatments.
White R; McIntosh C
J Wound Care; 2009 Aug; 18(8):335-41. PubMed ID: 19862873
[TBL] [Abstract][Full Text] [Related]
4. Apligraf in the treatment of neuropathic diabetic foot ulcers.
Edmonds M;
Int J Low Extrem Wounds; 2009 Mar; 8(1):11-8. PubMed ID: 19189997
[TBL] [Abstract][Full Text] [Related]
5. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing.
Brem H; Balledux J; Bloom T; Kerstein MD; Hollier L
Arch Surg; 2000 Jun; 135(6):627-34. PubMed ID: 10843357
[TBL] [Abstract][Full Text] [Related]
6. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers.
Niezgoda JA; Van Gils CC; Frykberg RG; Hodde JP
Adv Skin Wound Care; 2005 Jun; 18(5 Pt 1):258-66. PubMed ID: 15942317
[TBL] [Abstract][Full Text] [Related]
7. Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers.
Curran MP; Plosker GL
BioDrugs; 2002; 16(6):439-55. PubMed ID: 12463767
[TBL] [Abstract][Full Text] [Related]
8. Topical platelet-derived growth factor vs placebo therapy of diabetic foot ulcers offloaded with windowed casts: a randomized, controlled trial.
Ma C; Hernandez MA; Kirkpatrick VE; Liang LJ; Nouvong AL; Gordon II
Wounds; 2015 Apr; 27(4):83-91. PubMed ID: 25855851
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Wound Closure Rates Using a Human Fibroblast-derived Dermal Substitute Versus a Fetal Bovine Collagen Dressing: A Retrospective Study.
Fitzgerald RH; Sabolinski ML; Skornicki M
Wound Manag Prev; 2019 Sep; 65(9):26-34. PubMed ID: 31702990
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
Persson U; Willis M; Odegaard K; Apelqvist J
Value Health; 2000; 3 Suppl 1():39-46. PubMed ID: 16464208
[TBL] [Abstract][Full Text] [Related]
11. New treatments in ulcer healing and wound infection.
Edmonds M; Bates M; Doxford M; Gough A; Foster A
Diabetes Metab Res Rev; 2000; 16 Suppl 1():S51-4. PubMed ID: 11054889
[TBL] [Abstract][Full Text] [Related]
12. Comparison of characteristics and healing course of diabetic foot ulcers by etiological classification: neuropathic, ischemic, and neuro-ischemic type.
Yotsu RR; Pham NM; Oe M; Nagase T; Sanada H; Hara H; Fukuda S; Fujitani J; Yamamoto-Honda R; Kajio H; Noda M; Tamaki T
J Diabetes Complications; 2014; 28(4):528-35. PubMed ID: 24846054
[TBL] [Abstract][Full Text] [Related]
13. Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer.
Lantis JC; Boone D; Gendics C; Todd G
Adv Skin Wound Care; 2009 Apr; 22(4):167-71. PubMed ID: 19325276
[TBL] [Abstract][Full Text] [Related]
14. Treatment of diabetic foot ulcers using a blood bank platelet concentrate.
Jeong SH; Han SK; Kim WK
Plast Reconstr Surg; 2010 Mar; 125(3):944-52. PubMed ID: 20195121
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers.
Margolis DJ; Kantor J; Santanna J; Strom BL; Berlin JA
Diabetes Care; 2001 Mar; 24(3):483-8. PubMed ID: 11289472
[TBL] [Abstract][Full Text] [Related]
16. [Approval for recombinant growth factor. Since January 2000, patients with diabetic foot ulcers can be treated with the growth factor becaplermin (Regranex), manufactured with genetic technology].
Fruhstorfer B
Internist (Berl); 2000 Jan; 41(1):A38. PubMed ID: 10712088
[No Abstract] [Full Text] [Related]
17. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration.
O'Meara S; Cullum N; Majid M; Sheldon T
Health Technol Assess; 2000; 4(21):1-237. PubMed ID: 11074391
[TBL] [Abstract][Full Text] [Related]
18. [New developments in the treatment of diabetic foot ulcers].
Bakker K; Schaper NC
Ned Tijdschr Geneeskd; 2000 Feb; 144(9):409-12. PubMed ID: 10719543
[TBL] [Abstract][Full Text] [Related]
19. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers.
Langer A; Rogowski W
BMC Health Serv Res; 2009 Jul; 9():115. PubMed ID: 19591680
[TBL] [Abstract][Full Text] [Related]
20. The Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification independently predicts wound healing in diabetic foot ulcers.
Hicks CW; Canner JK; Mathioudakis N; Sherman R; Malas MB; Black JH; Abularrage CJ
J Vasc Surg; 2018 Oct; 68(4):1096-1103. PubMed ID: 29622357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
